Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
06 mars 2024 08h00 HE
|
Autonomix Medical, Inc.
First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) --...
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
29 févr. 2024 08h30 HE
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
23 févr. 2024 08h50 HE
|
Autonomix Medical, Inc.
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:...
Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
22 févr. 2024 08h00 HE
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Company expects to commence patient enrollment imminently...
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
16 févr. 2024 08h00 HE
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
14 févr. 2024 08h05 HE
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
06 févr. 2024 08h50 HE
|
Autonomix Medical, Inc.
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer On track to commence enrollment in Q1 2024 THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
01 févr. 2024 08h35 HE
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
31 janv. 2024 08h45 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
30 janv. 2024 12h00 HE
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...